Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its ...

Trump demanded that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...